Minimal information about T cell assays: the process of reaching the community of T cell immunologists in cancer and beyond
Open Access
- 16 November 2010
- journal article
- research article
- Published by Springer Nature in Cancer Immunology, Immunotherapy
- Vol. 60 (1) , 15-22
- https://doi.org/10.1007/s00262-010-0940-z
Abstract
Many assays to evaluate the nature, breadth, and quality of antigen-specific T cell responses are currently applied in human medicine. In most cases, assay-related protocols are developed on an individual laboratory basis, resulting in a large number of different protocols being applied worldwide. Together with the inherent complexity of cellular assays, this leads to unnecessary limitations in the ability to compare results generated across institutions. Over the past few years a number of critical assay parameters have been identified which influence test performance irrespective of protocol, material, and reagents used. Describing these critical factors as an integral part of any published report will both facilitate the comparison of data generated across institutions and lead to improvements in the assays themselves. To this end, the Minimal Information About T Cell Assays (MIATA) project was initiated. The objective of MIATA is to achieve a broad consensus on which T cell assay parameters should be reported in scientific publications and to propose a mechanism for reporting these in a systematic manner. To add maximum value for the scientific community, a step-wise, open, and field-spanning approach has been taken to achieve technical precision, user-friendliness, adequate incorporation of concerns, and high acceptance among peers. Here, we describe the past, present, and future perspectives of the MIATA project. We suggest that the approach taken can be generically applied to projects in which a broad consensus has to be reached among scientists working in fragmented fields, such as immunology. An additional objective of this undertaking is to engage the broader scientific community to comment on MIATA and to become an active participant in the project.Keywords
This publication has 29 references indexed in Scilit:
- Improved Survival with Ipilimumab in Patients with Metastatic MelanomaNew England Journal of Medicine, 2010
- Sipuleucel-T Immunotherapy for Castration-Resistant Prostate CancerNew England Journal of Medicine, 2010
- An integrative paradigm to impart quality to correlative scienceJournal of Translational Medicine, 2010
- Surrogate end points in the design of immunotherapy trials: emerging lessons from type 1 diabetesNature Reviews Immunology, 2010
- Vaccination against HPV-16 Oncoproteins for Vulvar Intraepithelial NeoplasiaNew England Journal of Medicine, 2009
- Colorectal Hepatic Metastases: Adjuvant Chemotherapy and SurvivalJournal of Clinical Oncology, 2009
- Immunogenicity and Antitumor Effects of Vaccination with Peptide Vaccine +/− Granulocyte-Monocyte Colony-Stimulating Factor and/or IFN-α2b in Advanced Metastatic Melanoma: Eastern Cooperative Oncology Group Phase II Trial E1696Clinical Cancer Research, 2009
- The cancer vaccine roller coasterNature Biotechnology, 2009
- Lessons from randomized phase III studies with active cancer immunotherapies – Outcomes from the 2006 Meeting of the Cancer Vaccine Consortium (CVC)Vaccine, 2007
- Comparison of cytokine ELISpot assay formats for the detection of islet antigen autoreactive T cellsJournal of Autoimmunity, 2003